Patents by Inventor Gerhard Siemeister
Gerhard Siemeister has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11976334Abstract: The present invention covers 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (in the following called “Compound A”), an inhibitor of ATR kinase, for use in a method of treating a hyper-proliferative disease in a subject.Type: GrantFiled: February 1, 2021Date of Patent: May 7, 2024Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Antje Margret Wengner, Gerhard Siemeister, Bernard Händler, Sven Golfier, Andreas Schlicker, Li Liu
-
Patent number: 11712440Abstract: The present invention covers an ATR kinase inhibitor, particularly 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(H-pyrazol-5-yl)-1,7-naphthyridine (“Compound A”), for use in the treatment of a hyper-proliferative disease in a subject, wherein the hyper-proliferative disease or the subject is or has been characterized by one or more biomarker(s), wherein the biomarker(s) comprise(s) a) one or more functional mutations in one or more gene(s)/protein(s) selected from RBBP8, APOBEC3A, APOBEC3B, CLSPN, ERCC, HUS1, MAD2L2, PGBD5, POLD1, RAD1, TIMELESS and/or TIPIN; and/or b) the expression of a fusion gene encoding a fusion protein selected from EWSR-ERG, EWSR1-FLI1, SS18-SSX and/or SS18-SSX2 gene/protein.Type: GrantFiled: December 4, 2018Date of Patent: August 1, 2023Assignee: Bayer AktiengesellschaftInventors: Antje Margret Wengner, Gerhard Siemeister, Li Liu
-
Publication number: 20230192700Abstract: The present invention provides compounds of general formula (I) in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 5, 2021Publication date: June 22, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Markus BERGER, Bernd BUCHMANN, Kai THEDE, Philipp BUCHGRABER, Gerhard SIEMEISTER, Patrick STEIGEMANN, Antje Margret WENGNER, Ulf BÖMER, Naomi BARAK, Philip LIENAU
-
Patent number: 11660301Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being an ATR kinase inhibitor, particularly Compound A, and component B being a PARP inhibitor, such as olaparib. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of a hyper-proliferative disease.Type: GrantFiled: February 22, 2018Date of Patent: May 30, 2023Assignee: Bayer Pharma AktiengesellschaftInventors: Antje Margret Wengner, Gerhard Siemeister
-
Publication number: 20230117034Abstract: The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 9, 2020Publication date: April 20, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Kai THEDE, Philipp BUCHGRABER, Gerhard SIEMEISTER, Patrick STEIGEMANN, Antje Margret WENGNER, Ulf BOEMER, Naomi BARAK, Philip LIENAU
-
Publication number: 20230106032Abstract: The present invention provides compounds of general formula (I): in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 5, 2021Publication date: April 6, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Kai THEDE, Philipp BUCHGRABER, Gerhard SIEMEISTER, Patrick STEIGEMANN, Antje Margret WENGNER, Ulf BÖMER, Naomi BARAK, Philip LIENAU
-
Patent number: 11529356Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 21, 2020Date of Patent: December 20, 2022Assignee: Bayer Pharma AktiengesellschaftInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Publication number: 20210404012Abstract: The present invention covers 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (in the following called “Compound A”), an inhibitor of ATR kinase, for use in a method of treating a hyper-proliferative disease in a subject.Type: ApplicationFiled: February 1, 2021Publication date: December 30, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Antje Margret WENGNER, Gerhard SIEMEISTER, Bernard HÄNDLER, Sven GOLFIER, Andreas SCHLICKER, Li LIU
-
Publication number: 20210369724Abstract: The present invention relates to combinations of: component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2) as defined herein, or a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof; and component B: one or more ATR kinase inhibitor(s) as defined herein, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof; and, optionally, component C: one or more further pharmaceutical agent(s); and, optionally, in which either or both of components A and B in any of the above-mentioned combinations are in the form of a pharmaceutical composition which is ready for use to be administered simultaneously, concurrently, separately or sequentially. The components may be administered independently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route.Type: ApplicationFiled: October 9, 2019Publication date: December 2, 2021Applicant: Bayer AktiengesellschaftInventors: Antje Margret WENGNER, Gerhard SIEMEISTER, Sylvia GRÜNEWALD, Bernard HAENDLER, Ningshu LIU
-
Publication number: 20210128572Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being an ATR kinase inhibitor, particularly Compound A, and component B being a PARP inhibitor, such as olaparib. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of a hyper-proliferative disease.Type: ApplicationFiled: February 22, 2018Publication date: May 6, 2021Applicant: Bayer Pharma AktiengesellschaftInventors: Antje Margret WENGNER, Gerhard SIEMEISTER
-
Publication number: 20200383991Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 21, 2020Publication date: December 10, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Publication number: 20200375997Abstract: The present invention covers an ATR kinase inhibitor, particularly 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(H-pyrazol-5-yl)-1,7-naphthyridine (“Compound A”), for use in the treatment of a hyper-proliferative disease in a subject, wherein the hyper-proliferative disease or the subject is or has been characterized by one or more biomarker(s), wherein the biomarker(s) comprise(s) a) one or more functional mutations in one or more gene(s)/protein(s) selected from RBBP8, APOBEC3A, APOBEC3B, CLSPN, ERCC, HUS1, MAD2L2, PGBD5, POLD1, RAD1, TIMELESS and/or TIPIN; and/or b) the expression of a fusion gene encoding a fusion protein selected from EWSR-ERG, EWSR1-FLI1, SS18-SSX and/or SS18-SSX2 gene/protein.Type: ApplicationFiled: December 4, 2018Publication date: December 3, 2020Applicant: Bayer AktiengesellschaftInventors: Antje Margret WENGNER, Gerhard SIEMEISTER, Li LIU
-
Patent number: 10772893Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 8, 2018Date of Patent: September 15, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Patent number: 10729680Abstract: The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: January 6, 2017Date of Patent: August 4, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Marcus Koppitz, Julien Lefranc, Lars Wortmann, Antje Margret Wengner, Gerhard Siemeister, Ulf Bömer, Benjamin Bader, Philip Lienau, Hans Schick
-
Patent number: 10717749Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: September 26, 2016Date of Patent: July 21, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Jens Geisler, Daniel Hog, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Kunzeng Zheng, Ping Gao, Gang Chen, Jiajun Xi, Simon Anthony Herbert, Gerhard Siemeister, Nicolas Werbeck
-
Publication number: 20200216439Abstract: Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals.Type: ApplicationFiled: December 12, 2016Publication date: July 9, 2020Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Gerhard SIEMEISTER, Ursula MÖNNING, Franz VON NUSSBAUM
-
Patent number: 10604532Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.Type: GrantFiled: March 21, 2019Date of Patent: March 31, 2020Assignees: Bayer Intellectual Property GmbH, Bayer Pharma AktiengesellschaftInventors: Marion Hitchcock, Anne Mengel, Vera Pütter, Gerhard Siemeister, Antje Margret Wengner, Hans Briem, Knut Eis, Volker Schulze, Amaury Ernesto Fernandez-Montalvan, Stefan Prechtl, Simon Holton, Jörg Fanghänel, Philip Lienau, Cornelia Preusse, Mark Jean Gnoth
-
Publication number: 20200063212Abstract: The present invention covers 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyra-zol-5-yl)-1,7-naphthyridine (in the following called “Compound A”), an inhibitor of ATR kinase, for use in a method of treating a hyper-proliferative disease in a subject.Type: ApplicationFiled: February 22, 2018Publication date: February 27, 2020Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Antje Margret WENGNER, Gerhard SIEMEISTER, Bernard HÄNDLER, Sven GOLFIER, Andreas SCHLICKER, Li LIU
-
Patent number: 10428044Abstract: Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.Type: GrantFiled: June 17, 2015Date of Patent: October 1, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Keith Graham, Ulrich Klar, Hans Briem, Marion Hitchcock, Lars Bärfacker, Knut Eis, Volker Schulze, Gerhard Siemeister, Wilhelm Bone, Jens Schröder, Simon Holton, Philip Lienau, René Tempel, Helmut Sonnenschein, Jozsef Bálint, Heinz Graubaum
-
Patent number: 10428063Abstract: Compound of formula (I), processes for their production and their use as pharmaceuticals.Type: GrantFiled: January 25, 2016Date of Patent: October 1, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Keith Graham, Ulrich Klar, Hans Briem, Volker Schulze, Gerhard Siemeister, Philip Lienau, René Tempel, Jozsef Bálint